RNS Number : 6298W

Zotefoams PLC

26 April 2021

Zotefoams plc

(the 'Company' or the 'Group')

2020 Annual Report, Notice of the 2021 Annual General Meeting and Investors Presentation

26 April 2021 - The Company has published its 2020 Annual Report and the Notice of the 2021 Annual General Meeting to be held at 675 Mitcham Road, Croydon CR9 3AL on 26 May 2021 at 10.00 a.m. on:



In compliance with Listing Rule 9.6.1, the following documents have been submitted to the National Storage Mechanism and will shortly be available for inspection at:


1. Annual Report for the year ended 31 December 2020, incorporating the Notice of the 2021 Annual General Meeting; and

   2.   Form of Proxy for the 2021 Annual General Meeting. 

A condensed set of the financial statements, the Chair's introduction, the Group CEO's review and the Group CFO's review in respect of the Annual Report were included in the unaudited preliminary results announcement issued on 23 March 2021, which may be found at:


This announcement contains, in Annex A, additional information for the purposes of compliance with the Disclosure and Transparency Rules, including the statement of Directors' responsibilities in respect of the financial statements, a description relating to principal risks and uncertainties, and details of related party transactions. This information is extracted from the 2020 Annual Report. This announcement is not a substitute for reading the full Annual Report. Page and note references in the text below refer to page numbers and notes in the 2020 Annual Report.

In light of the COVID-19 pandemic and the UK Government's current guidance regarding social distancing and the prohibition of public gatherings, the arrangements and format of the Annual General Meeting (AGM) have been altered this year in order to protect the health and wellbeing of shareholders and other attendees. Accordingly, the Company will make arrangements such that the legal requirements to hold the AGM can be satisfied through the attendance of a minimum number of people.

While it is with regret that shareholders are requested not to attend the AGM, a separate presentation open to all existing and potential shareholders will be held after the AGM on 26 May 2021 at 11.00am on the Investor Meet Company platform:

https://www.investormeetcompany.com/zotefoams-plc/register-investor .

Investors who already follow Zotefoams plc on the Investor Meet Company platform will automatically be invited.

In addition, new articles provisions are being proposed to allow hybrid AGMs to be held in the future. The proposed provisions do not allow solely virtual general meetings to be held and the Company is committed, where possible in future, to hold physical general meetings.

Shareholders are strongly encouraged to submit a proxy form indicating their votes in accordance with the notes below and email any question for the Board to investorinfo@zotefoams.com a minimum of 48 hours prior to the AGM. The Board will do its best to answer these questions either during, or immediately after, the AGM, by email.

The Board continues to monitor the pandemic-affected situation and will make any further announcement, if required, through the release of a RNS and on the AGM page of the Company's website: https://www.zotefoams.com/agm/ .


Lydia Harratt

Group Company Secretary

Zotefoams plc

020 8664 1600

About Zotefoams plc

Zotefoams plc (LSE - ZTF) is a world leader in cellular materials technology delivering optimal material solutions for the benefit of society. Utilising a variety of unique manufacturing processes, including environmentally friendly nitrogen expansion for lightweight AZOTE(R) polyolefin and ZOTEK(R) high-performance foams, Zotefoams sells to diverse markets worldwide. Zotefoams uses its own cellular materials to manufacture T-FIT(R) advanced insulation for demanding industrial markets. Zotefoams also owns and licenses patented microcellular foam technology to reduce plastic use in extrusion applications and for ReZorce(R) mono-material recyclable barrier packaging.

Zotefoams is headquartered in Croydon, UK, with additional manufacturing sites in Kentucky, USA and Brzeg, Poland (foam manufacture), Oklahoma, USA (foam products manufacture and conversion), Massachusetts, USA (MuCell Extrusion) and Jiangsu Province, China (T-FIT).


AZOTE(R), ZOTEK(R), ReZorce(R) and T-FIT(R) are registered trademarks of Zotefoams plc.

Annex A

Statement of Directors' responsibilities in respect of the financial statements

The Directors consider the Annual Report, taken as a whole, to be fair, balanced and understandable.

The Directors are responsible for preparing the Annual Report and the financial statements in accordance with applicable law and regulation.

Company law requires the Directors to prepare financial statements for each financial year. Under that law the Directors have prepared the Consolidated and Company financial statements in accordance with International Financial Reporting Standards (IFRSs) as adopted by the European Union. Under company law the Directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Group and Company and of the profit or loss of the Group and Company for that period. In preparing the financial statements, the Directors are required to:

   --           select suitable accounting policies and then apply them consistently; 

-- state whether applicable IFRSs as adopted by the European Union have been followed for the Consolidated and Company financial statements, subject to any material departures disclosed and explained in the financial statements;

   --           make judgements and accounting estimates that are reasonable and prudent; and 

-- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the Group and Company will continue in business.

The Directors are also responsible for safeguarding the assets of the Group and Company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The Directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Group's and Company's transactions and disclose with reasonable accuracy at any time the financial position of the Group and Company and enable them to ensure that the financial statements and the Directors' Remuneration report comply with the Companies Act 2006 and, as regards the consolidated financial statements, Article 4 of the IAS Regulation.

The Directors are responsible for the maintenance and integrity of the Company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

The Directors consider that the Annual Report, taken as a whole, is fair, balanced and understandable and provides the information necessary for shareholders to assess the position and performance, business model and strategy of the Group and Company.

Each of the Directors, whose names and functions are listed on pages 60 and 61 of the Annual Report, confirm that, to the best of their knowledge:

-- the Consolidated and Company financial statements, which have been prepared in accordance with IFRSs as adopted by the European Union, give a true and fair view of the assets, liabilities, financial position and profit of the Group and Company;

-- the Group CEO's review includes a fair review of the development and performance of the business and the position of the Group and Company; and

-- the principal risks and uncertainties faced by the Group and the Company are described on pages 36 to 42 of the Annual Report.

Principal risks and uncertainties

The details of our principal risks and uncertainties and the key mitigating activities can be found on pages 36 to 42. We are disclosing those risks and uncertainties that we believe have the greatest impact in achieving our strategic objectives. The Group is exposed to a wide range of risks in addition to those listed, and these are managed through the risk management framework shown on page 33. This framework enables us to monitor for any increase in likelihood or impact and ensure that we have the appropriate mitigations in place.

Zotefoams' risk profile will evolve as the business grows at its targeted pace, although we expect these principal risks and uncertainties to remain broadly consistent. Following a detailed reassessment of our thinking and approach to risk management in the previous year, and having assessed the inputs from our risk framework mechanism during the current year, we have concluded that there are no changes to our assessment.

Related party transactions


The Directors of the Company as at 31 December 2020 and their immediate relatives control approximately 1.1% (2019: 1.2%) of the voting shares of the Company. Details of Directors' pay and remuneration are given in the Remuneration report on pages 72 to 80. Executive Directors are considered to be the only key management personnel. Details of compensation paid to key management personnel are included in note 6.

Subsidiaries and joint venture

Details of the joint venture and subsidiaries of the Company are set out in notes 10 and 14. These companies are considered to be related parties.

The following material transactions were carried out with related parties:

                                                  2020      2019 
                                                 GBP'000   GBP'000 
                                                --------  -------- 
Sale of goods: subsidiaries of the Company       6,465     7,481 
                                                --------  -------- 
Sale of services: subsidiaries of the Company     760      1,636 
----------------------------------------------  --------  -------- 
Loans given (net of repayments): subsidiaries 
 of the Company                                  8,606     15,683 
----------------------------------------------  --------  -------- 
Interest income: subsidiaries of the Company      569       101 
----------------------------------------------  --------  -------- 
Sale of goods: joint venture of the Company      2,155     3,112 
----------------------------------------------  --------  -------- 
Sale of service: joint venture of the Company     407       813 
----------------------------------------------  --------  -------- 
Total                                            18,962    28,826 
----------------------------------------------  --------  -------- 

Balances between the Company and its active subsidiaries and joint venture are as follows:

                                 Receivable from/(payable 
                                            to)               Investment in 
                                --------------------------  ------------------ 
                                    2020          2019        2020      2019 
                                   GBP'000       GBP'000     GBP'000   GBP'000 
                                ------------  ------------  --------  -------- 
Zotefoams Inc.                     9,426         9,204         -         - 
                                ------------  ------------  --------  -------- 
KZ Trading and Investment 
 Ltd                               1,498         1,895         -         - 
                                ------------  ------------  --------  -------- 
Azote Asia Limited                  896           907          -         - 
                                ------------  ------------  --------  -------- 
MuCell Extrusion LLC               3,424           96          -         - 
                                ------------  ------------  --------  -------- 
Zotefoams International 
 Limited                           15,087        14,317      30,822    30,576 
                                ------------  ------------  --------  -------- 
Zotefoams Operations Limited         76            1           -         - 
                                ------------  ------------  --------  -------- 
Zotefoams T-Fit Material 
 Technology (Kunshan) Limited      2,402           22          -         - 
                                ------------  ------------  --------  -------- 
Zotefoams Poland Sp. z.o.o.         523           809          -         - 
                                ------------  ------------  --------  -------- 
Zotefoams France                    (30)           -           -         - 
------------------------------  ------------  ------------  --------  -------- 
T-Fit Insulation Solutions 
 India Private Limited              379           131          -         - 
------------------------------  ------------  ------------  --------  -------- 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

April 26, 2021 10:16 ET (14:16 GMT)

Zotefoams (LSE:ZTF)
Gráfica de Acción Histórica
De Dic 2021 a Ene 2022 Haga Click aquí para más Gráficas Zotefoams.
Zotefoams (LSE:ZTF)
Gráfica de Acción Histórica
De Ene 2021 a Ene 2022 Haga Click aquí para más Gráficas Zotefoams.